"Front-line Osimertinib Improves OS In EGFR-mutated Lung Cancer" - John DeRosier
Osimertinib significantly extended OS compared with standard epidermal growth factor receptor tyrosine kinase inhibitors as front-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to late-breaking results of the randomized phase 3 FLAURA study presented at European Society for Medical Oncology Congress. According to Nicholas Rohs, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai who was not involved in the study, “I consider this practice-reaffirming data. In my opinion, osimertinib had already proven itself a preferred first-line option with the known PFS benefit, good brain penetration and favorable tolerance. To have the OS benefit just solidifies that for me.” He added, “It highlights the need for re-genotyping these patients either via liquid or tissue biopsy at progression, and to design clinical trials to evaluate the best way to approach these patients with either sequential or concurrent targeted therapies.”
— Nicholas Rohs, MD, Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Mount Sinai Health System